216 related articles for article (PubMed ID: 37254186)
1. Effects of SGLT-2 inhibitors on adipose tissue distribution in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
Wang X; Wu N; Sun C; Jin D; Lu H
Diabetol Metab Syndr; 2023 May; 15(1):113. PubMed ID: 37254186
[TBL] [Abstract][Full Text] [Related]
2. Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
Pan R; Zhang Y; Wang R; Xu Y; Ji H; Zhao Y
PLoS One; 2022; 17(12):e0279889. PubMed ID: 36584211
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Influence of glucagon-like peptide-1 receptor agonists on fat accumulation in patients with diabetes mellitus and non-alcoholic fatty liver disease or obesity: A systematic review and meta-analysis of randomized control trials.
Xie W; Hong Z; Li B; Huang B; Dong S; Cai Y; Ruan L; Xu Q; Mou L; Zhang Y
J Diabetes Complications; 2024 Jun; 38(6):108743. PubMed ID: 38688179
[TBL] [Abstract][Full Text] [Related]
5. GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis.
Yan H; Huang C; Shen X; Li J; Zhou S; Li W
Front Endocrinol (Lausanne); 2022; 13():923606. PubMed ID: 35909522
[TBL] [Abstract][Full Text] [Related]
6. Influence of Sodium-Glucose Cotransporter-2 Inhibitors on Plasma Adiponectin in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.
Wang Y; Xia N
Horm Metab Res; 2022 Dec; 54(12):833-844. PubMed ID: 36049756
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Zhu Y; Xu J; Zhang D; Mu X; Shi Y; Chen S; Wu Z; Li S
Front Endocrinol (Lausanne); 2021; 12():769069. PubMed ID: 34956080
[TBL] [Abstract][Full Text] [Related]
8. Effects of sodium-glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis.
Hu X; Yang Y; Hu X; Jia X; Liu H; Wei M; Lyu Z
Diabetes Obes Metab; 2022 Feb; 24(2):228-238. PubMed ID: 34617381
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of liraglutide on reducing visceral and ectopic fat in adults with or without type 2 diabetes mellitus: A systematic review and meta-analysis.
He F; Chen W; Xu W; Liu D; Xiao Z; Tang Y; Lin Z; Liao Y; Bin J; Chen G; Chen Y
Diabetes Obes Metab; 2023 Mar; 25(3):664-674. PubMed ID: 36314246
[TBL] [Abstract][Full Text] [Related]
10. Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Zhang S; Qi Z; Wang Y; Song D; Zhu D
Front Endocrinol (Lausanne); 2023; 14():1203666. PubMed ID: 37465122
[TBL] [Abstract][Full Text] [Related]
11. An Update on the Effect Of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease: A Systematic Review of Clinical Trials.
Alfayez AI; Alfallaj JM; Mobark MA; Alalwan AA; Alfayez OM
Curr Diabetes Rev; 2024; 20(2):e250523217349. PubMed ID: 37231725
[TBL] [Abstract][Full Text] [Related]
12. Effect of SGLT-2 inhibitors on cardiac autonomic function in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.
Patoulias D; Katsimardou A; Fragakis N; Papadopoulos C; Doumas M
Acta Diabetol; 2023 Jan; 60(1):1-8. PubMed ID: 35986116
[TBL] [Abstract][Full Text] [Related]
13. Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
Lu J; Tang L; Meng H; Zhao J; Liang Y
Diabetes Metab Res Rev; 2019 Oct; 35(7):e3169. PubMed ID: 30974510
[TBL] [Abstract][Full Text] [Related]
14. Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.
Wei Q; Xu X; Guo L; Li J; Li L
Front Endocrinol (Lausanne); 2021; 12():635556. PubMed ID: 34220701
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Singh AK; Singh R
Diabetes Metab Syndr; 2021; 15(1):351-359. PubMed ID: 33503584
[TBL] [Abstract][Full Text] [Related]
16. The effects of Sodium-glucose cotransporter 2 inhibitors on adipose tissue in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Liu X; Chen Y; Liu T; Cai L; Yang X; Mou C
Front Endocrinol (Lausanne); 2023; 14():1115321. PubMed ID: 36777342
[TBL] [Abstract][Full Text] [Related]
17. Sodium-glucose cotransporter-2 inhibitors improve liver enzymes in patients with co-existing non-alcoholic fatty liver disease: a systematic review and meta-analysis.
Amjad W; Malik A; Qureshi W; Dennis B; Mumtaz M; Haider R; Jamal S; Jaura F; Ahmed A
Prz Gastroenterol; 2022; 17(4):288-300. PubMed ID: 36514450
[TBL] [Abstract][Full Text] [Related]
18. The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis.
Liao C; Liang X; Zhang X; Li Y
PLoS One; 2023; 18(8):e0289616. PubMed ID: 37616255
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
Li CX; Liang S; Gao L; Liu H
PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
[TBL] [Abstract][Full Text] [Related]
20. Relationship Between SGLT-2i and Ocular Diseases in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.
Zhou B; Shi Y; Fu R; Ni H; Gu L; Si Y; Zhang M; Jiang K; Shen J; Li X; Sun X
Front Endocrinol (Lausanne); 2022; 13():907340. PubMed ID: 35692406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
